Amryt Supports Acromegaly Awareness Day 2022
31. Oktober 2022 07:00 ET
|
Amryt Pharma plc
Amryt Supports Acromegaly Awareness Day 2022 DUBLIN, Ireland, and Boston MA, October 31, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to...
The British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis Bullosa
25. Oktober 2022 07:00 ET
|
Amryt Pharma plc
The British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis Bullosa DUBLIN, Ireland, and Boston MA, October 25, 2022 Amryt (Nasdaq: AMYT), a global,...
Amryt Supports Global EB Awareness Week 2022
24. Oktober 2022 07:00 ET
|
Amryt Pharma plc
Amryt Supports Global EB Awareness Week 2022 DUBLIN, Ireland, and Boston MA, October 24, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to...
Amryt to Report Q3 2022 Results on November 3, 2022
19. Oktober 2022 07:00 ET
|
Amryt Pharma plc
Amryt to Report Q3 2022 Results on November 3, 2022 DUBLIN, Ireland, and Boston MA, October 19, 2022, Amryt (Nasdaq: AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring,...
COMP adopts positive opinion on Orphan Disease Designation for Mycapssa® for the treatment of Acromegaly
18. Oktober 2022 07:00 ET
|
Amryt Pharma plc
COMP adopts positive opinion on Orphan Disease Designation for Mycapssa® for the treatment of Acromegaly DUBLIN, Ireland, and Boston MA, October 18, 2022 Amryt (Nasdaq: AMYT), a global,...
Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)
17. Oktober 2022 07:00 ET
|
Amryt Pharma plc
Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin) DUBLIN, Ireland, and Boston MA, October 17, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage...
Amryt Supports FH Awareness Day – September 24, 2022
23. September 2022 07:00 ET
|
Amryt Pharma plc
Amryt Supports FH Awareness Day – September 24, 2022 DUBLIN, Ireland, and Boston MA, September 23, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company...
CHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly
16. September 2022 07:30 ET
|
Amryt Pharma plc
CHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly Positive opinion based on MPOWERED Phase 3 trial DUBLIN, Ireland, and Boston MA, September 16, 2022, Amryt (Nasdaq:...
Amryt Announces New Patent for Mycapssa®
13. September 2022 07:00 ET
|
Amryt Pharma plc
Amryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, September 13, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring,...
Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great Britain
08. September 2022 07:00 ET
|
Amryt Pharma plc
Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great Britain UK MHRA approval follows on from recent European Commission approval of Filsuvez® DUBLIN,...